About CNS Therapeutics
CNS Therapeutics is a company based in Saint Paul (United States) founded in 2007 by Richard Penn was acquired by Mallinckrodt Pharmaceuticals in September 2012.. CNS Therapeutics has raised $13.1 million across 3 funding rounds from investors including Mallinckrodt Pharmaceuticals, Thomas, McNerney & Partners and InterWest. CNS Therapeutics operates in a competitive market with competitors including Flexion Therapeutics, Eliem Therapeutics, Zogenix, Heron Therapeutics and Egalet, among others.
- Headquarter Saint Paul, United States
- Founders Richard Penn
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Cns Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$13.1 M (USD)
in 3 rounds
-
Latest Funding Round
$3.05 M (USD), Series A
Dec 21, 2012
-
Investors
Mallinckrodt Pharmaceuticals
& 2 more
-
Employee Count
Employee Count
-
Acquired by
Mallinckrodt Pharmaceuticals
(Sep 24, 2012)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of CNS Therapeutics
CNS Therapeutics has successfully raised a total of $13.1M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $3.05 million completed in December 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series A — $3.0M
-
First Round
First Round
(18 Aug 2009)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2012 | Amount | Series A - CNS Therapeutics | Valuation |
investors |
|
| Dec, 2010 | Amount | Series A - CNS Therapeutics | Valuation |
investors |
|
| Aug, 2009 | Amount | Series A - CNS Therapeutics | Valuation | Thomas, McNerney & Partners , InterWest Partners |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in CNS Therapeutics
CNS Therapeutics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Mallinckrodt Pharmaceuticals, Thomas, McNerney & Partners and InterWest. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Early-stage investing in IT and healthcare ventures.
|
Founded Year | Domain | Location | |
|
Specialty pharmaceutical products and diagnostic imaging agents are manufactured.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by CNS Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - CNS Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cns Therapeutics Comparisons
Competitors of CNS Therapeutics
CNS Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Eliem Therapeutics, Zogenix, Heron Therapeutics and Egalet, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| domain | founded_year | HQ Location |
Develops antibody-based treatments for autoimmune and inflammatory disorders.
|
|
| domain | founded_year | HQ Location |
Drug delivery systems for CNS disorders and pain are developed.
|
|
| domain | founded_year | HQ Location |
Reformulated injectables for chemotherapy side effects and pain are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for pain management are developed with abuse-deterrent designs.
|
|
| domain | founded_year | HQ Location |
Therapies for pain and addiction treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cns Therapeutics
Frequently Asked Questions about CNS Therapeutics
When was CNS Therapeutics founded?
CNS Therapeutics was founded in 2007 and raised its 1st funding round 2 years after it was founded.
Where is CNS Therapeutics located?
CNS Therapeutics is headquartered in Saint Paul, United States. It is registered at Saint Paul, Minnesota, United States.
Is CNS Therapeutics a funded company?
CNS Therapeutics is a funded company, having raised a total of $13.1M across 3 funding rounds to date. The company's 1st funding round was a Series A of $7M, raised on Aug 18, 2009.
What does CNS Therapeutics do?
CNS Therapeutics was founded in 2007 in Saint Paul, United States, within the biopharmaceutical sector. Site-specific drugs for neurological disorders and chronic pain are developed, including Gablofen, a baclofen injection used to treat severe spasticity via intrathecal administration in pre-filled syringes and vials. Operations focus on pain management solutions. The company was acquired by Mallinckrodt in 2012, later integrated into Covidien, and subsequently into Medtronic.
Who are the top competitors of CNS Therapeutics?
CNS Therapeutics's top competitors include Flexion Therapeutics, Cara Therapeutics and Satsuma Pharmaceuticals.
Who are CNS Therapeutics's investors?
CNS Therapeutics has 3 investors. Key investors include Mallinckrodt Pharmaceuticals, Thomas, McNerney & Partners, and InterWest.